Literature DB >> 24032595

Transglutaminase 2 accelerates neuroinflammation in amyotrophic lateral sclerosis through interaction with misfolded superoxide dismutase 1.

Miki Oono1, Ayako Okado-Matsumoto, Akemi Shodai, Akemi Ido, Yasuyuki Ohta, Koji Abe, Takashi Ayaki, Hidefumi Ito, Ryosuke Takahashi, Naoyuki Taniguchi, Makoto Urushitani.   

Abstract

Although the aberrant assembly of mutant superoxide dismutase 1 (mSOD1) is implicated in the pathogenesis of familial amyotrophic lateral sclerosis (ALS), the molecular basis of superoxide dismutase 1 (SOD1) oligomerization remains undetermined. We investigated the roles of transglutaminase 2 (TG2), an endogenous cross-linker in mSOD1-linked ALS. TG2 interacted preferentially with mSOD1 and promoted its oligomerization in transfected cells. Purified TG2 directly oligomerized recombinant mutant SOD1 and the apo-form of the wild-type SOD1 proteins in a calcium-dependent manner, indicating that misfolded SOD1 is a substrate of TG2. Moreover, the non-cell-autonomous effect of extracellular TG2 on the neuroinflammation was suggested, since the TG2-mediated soluble SOD1 oligomers induced tumor necrosis factor-α, interleukin-1β, and nitric oxide in microglial BV2 cells. TG2 was up-regulated in the spinal cord of pre-symptomatic G93A SOD1 transgenic mice and in the hypoglossal nuclei of mice suffering nerve ligation. Furthermore, inhibition of spinal TG2 by cystamine significantly delayed the progression and reduced SOD1 oligomers and microglial activation. These results indicate a novel role of TG2 in SOD1 oligomer-mediated neuroinflammation, as well as in the involvement in the intracellular aggregation of misfolded SOD1 in ALS.
© 2013 International Society for Neurochemistry.

Entities:  

Keywords:  amyotrophic lateral sclerosis; microglia; non-cell-autonomous; oligomer; superoxide dismutase 1; transglutaminase 2

Mesh:

Substances:

Year:  2013        PMID: 24032595     DOI: 10.1111/jnc.12441

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

1.  Parsing disease-relevant protein modifications from epiphenomena: perspective on the structural basis of SOD1-mediated ALS.

Authors:  N D Schmitt; J N Agar
Journal:  J Mass Spectrom       Date:  2017-07       Impact factor: 1.982

Review 2.  Post-translational modifications of tubulin: pathways to functional diversity of microtubules.

Authors:  Yuyu Song; Scott T Brady
Journal:  Trends Cell Biol       Date:  2014-11-25       Impact factor: 20.808

Review 3.  Therapeutic Applications of Cysteamine and Cystamine in Neurodegenerative and Neuropsychiatric Diseases.

Authors:  Bindu D Paul; Solomon H Snyder
Journal:  Front Neurol       Date:  2019-12-12       Impact factor: 4.003

Review 4.  Transglutaminase 2 as a Marker for Inflammation and Therapeutic Target in Sepsis.

Authors:  Ting Su; Xian-Yang Qin; Yutaka Furutani
Journal:  Int J Mol Sci       Date:  2021-02-14       Impact factor: 5.923

5.  Comparative Profiling of TG2 and Its Effectors in Human Relapsing Remitting and Progressive Multiple Sclerosis.

Authors:  Damien D Pearse; Andrew B Hefley; Alejo A Morales; Mousumi Ghosh
Journal:  Biomedicines       Date:  2022-05-26

6.  Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53.

Authors:  Patrizia Malkomes; Ilaria Lunger; Elsie Oppermann; Khalil Abou-El-Ardat; Thomas Oellerich; Stefan Günther; Can Canbulat; Sabrina Bothur; Frank Schnütgen; Weijia Yu; Susanne Wingert; Nadine Haetscher; Claudia Catapano; Marina S Dietz; Mike Heilemann; Hans-Michael Kvasnicka; Katharina Holzer; Hubert Serve; Wolf Otto Bechstein; Michael A Rieger
Journal:  Oncogene       Date:  2021-06-08       Impact factor: 9.867

7.  Ablation of polyamine catabolic enzymes provokes Purkinje cell damage, neuroinflammation, and severe ataxia.

Authors:  Kamyar Zahedi; Marybeth Brooks; Sharon Barone; Negah Rahmati; Tracy Murray Stewart; Matthew Dunworth; Christina Destefano-Shields; Nupur Dasgupta; Steve Davidson; Diana M Lindquist; Christine E Fuller; Roger D Smith; John L Cleveland; Robert A Casero; Manoocher Soleimani
Journal:  J Neuroinflammation       Date:  2020-10-14       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.